2021
DOI: 10.1016/j.nicl.2021.102750
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the early-phase [18F]AV45 PET as an optimal surrogate of [18F]FDG PET in ageing and Alzheimer’s clinical syndrome

Abstract: Highlights Exhaustive vertex-wise quantitative analyses to validate eAV45 as an optimal proxy for 18 F-FDG PET. Optimal early time frame 0–4 min maximizes both within- and inter-subject correlations of eAV45 with 18 F-FDG PET. Optimal early time frame 0–4 min minimizes both within- and inter-subject correlations of eAV45 with lAV45. Balanced accuracies of neurodegenera… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
44
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 9 publications
(45 citation statements)
references
References 58 publications
0
44
0
1
Order By: Relevance
“…Overall, 12 AD patients and 10 controls underwent lumbar puncture for CSF collection, and the other 18 underwent Florbetapir F-18 (18F-AV-45) positron emission tomography (PET)-computed tomography or PET–magnetic resonance scanning. A low CSF Aβ42 level or a positive 18F-AV-45 PET scan, which showed a high binding affinity and specificity to Aβ plaques, were additional requirements for inclusion in the AD group to confirm that patients had amyloid deposition in the brain [ 36 ].…”
Section: Methodsmentioning
confidence: 99%
“…Overall, 12 AD patients and 10 controls underwent lumbar puncture for CSF collection, and the other 18 underwent Florbetapir F-18 (18F-AV-45) positron emission tomography (PET)-computed tomography or PET–magnetic resonance scanning. A low CSF Aβ42 level or a positive 18F-AV-45 PET scan, which showed a high binding affinity and specificity to Aβ plaques, were additional requirements for inclusion in the AD group to confirm that patients had amyloid deposition in the brain [ 36 ].…”
Section: Methodsmentioning
confidence: 99%
“…We also investigated, if significant associations between the VRF of interest and changes in RSFC over time were moderated by Aβ burden. Therefore, we dichotomized participants with an Aβ-PET SUVR ≥ 1.22 into Aβ-positive individuals and < 1.22 into Aβ-negative individuals, using thresholds that were established and described in our previous study ( Vanhoutte et al, 2021 ). Then the models described above were rerun, except that the term “Aβ-PET SUVR × time” was replaced by a 3-way interaction between the vascular risk factor of interest (i.e., that was significantly associated with RSFC in the first models), Aβ positivity status and time.…”
Section: Methodsmentioning
confidence: 99%
“…임상에서 아밀로이드 PET가 사용되기 전에는 알츠하이머병의 진단에서 FDG PET를 주로 사용하여 신경퇴행을 평가하였으나, 아밀로이드병리의 정보를 함께 얻기 위해서 FDG PET와 아밀로이드 PET를 모두 얻는 경우 시간적 경제적 부담과 방사선 노출이 증가할 수밖에 없다. 현재 사용되고 있는 아밀로이드 영상용 방사성 의약품들은 지질친화도가 높아 정맥 주사 후 매우 짧은 시간 이내에 뇌로 들어가는데, 주사 후 초기 섭취는 뇌혈류량을 반영하게 되고, 이는 FDG PET에서 측정되는 뇌포도당대사와 잘 매칭된다( 33 34 ). Fig.…”
Section: 아밀로이드 Pet의 임상적 평가과 응용unclassified